AR097971A1 - Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas - Google Patents
Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellasInfo
- Publication number
- AR097971A1 AR097971A1 ARP140103759A ARP140103759A AR097971A1 AR 097971 A1 AR097971 A1 AR 097971A1 AR P140103759 A ARP140103759 A AR P140103759A AR P140103759 A ARP140103759 A AR P140103759A AR 097971 A1 AR097971 A1 AR 097971A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound represented
- appear
- diffraction pattern
- powder diffraction
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 12
- -1 sulfur trioxylamine Chemical compound 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 125000006239 protecting group Chemical group 0.000 abstract 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003463 adsorbent Substances 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000012043 crude product Substances 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000011033 desalting Methods 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000010899 nucleation Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000006798 ring closing metathesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013211242 | 2013-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097971A1 true AR097971A1 (es) | 2016-04-20 |
Family
ID=52813113
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103759A AR097971A1 (es) | 2013-10-08 | 2014-10-08 | Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas |
| ARP240100517A AR132030A2 (es) | 2013-10-08 | 2024-03-01 | Proceso de producción de formas cristalinas de derivado de diazabiciclooctano |
| ARP240100516A AR132029A2 (es) | 2013-10-08 | 2024-03-01 | Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida |
| ARP240100515A AR132028A2 (es) | 2013-10-08 | 2024-03-01 | Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100517A AR132030A2 (es) | 2013-10-08 | 2024-03-01 | Proceso de producción de formas cristalinas de derivado de diazabiciclooctano |
| ARP240100516A AR132029A2 (es) | 2013-10-08 | 2024-03-01 | Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida |
| ARP240100515A AR132028A2 (es) | 2013-10-08 | 2024-03-01 | Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10131665B2 (enExample) |
| EP (4) | EP3067355B1 (enExample) |
| JP (3) | JP6617029B2 (enExample) |
| KR (2) | KR102487297B1 (enExample) |
| CN (2) | CN105612159A (enExample) |
| AR (4) | AR097971A1 (enExample) |
| AU (1) | AU2014332960B2 (enExample) |
| BR (2) | BR122022016622B1 (enExample) |
| CA (2) | CA3110803C (enExample) |
| DK (1) | DK3067355T3 (enExample) |
| ES (2) | ES2842225T3 (enExample) |
| HK (1) | HK1219479A1 (enExample) |
| HU (1) | HUE051925T2 (enExample) |
| IL (2) | IL244969B (enExample) |
| MX (2) | MX361659B (enExample) |
| MY (1) | MY199066A (enExample) |
| NZ (5) | NZ757221A (enExample) |
| RU (1) | RU2695219C2 (enExample) |
| SG (1) | SG11201602723RA (enExample) |
| TW (1) | TWI673269B (enExample) |
| WO (1) | WO2015053297A1 (enExample) |
| ZA (1) | ZA201602054B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117734C2 (uk) | 2012-05-30 | 2018-09-25 | Мейдзі Сейка Фарма Ко., Лтд. | НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ |
| MY176278A (en) | 2013-09-24 | 2020-07-27 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative and intermediate thereof |
| NZ757221A (en) | 2013-10-08 | 2021-12-24 | Meiji Seika Pharma Co Ltd | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| BR112017010445B8 (pt) * | 2014-12-05 | 2024-02-27 | Meiji Seika Pharma Co Ltd | Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável |
| US10208041B2 (en) * | 2016-10-07 | 2019-02-19 | Hoffman-La Roche Inc. | Diazabicyclooctane compounds |
| SG11202000217QA (en) | 2017-07-21 | 2020-02-27 | Antabio Sas | Chemical compounds |
| KR20200091396A (ko) | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조 방법 |
| CA3076959C (en) * | 2017-09-27 | 2025-02-11 | Meiji Seika Pharma Co., Ltd. | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND THEIR PRODUCTION PROCESS |
| TW201920174A (zh) * | 2017-09-27 | 2019-06-01 | 瑞士商羅氏大藥廠股份有限公司 | 二氮雜雙環辛烷衍生物之醫藥形式及其製法 |
| CN107991404B (zh) * | 2017-11-23 | 2021-01-08 | 中山奕安泰医药科技有限公司 | 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法 |
| CN107941944B (zh) * | 2017-11-23 | 2020-09-15 | 中山奕安泰医药科技有限公司 | 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法 |
| EP3572411A1 (en) | 2018-05-21 | 2019-11-27 | Antabio SAS | Thiazole derivatives as metallo-beta-lactamase inhibitors |
| US11897844B2 (en) * | 2018-09-21 | 2024-02-13 | Api Corporation | Method for producing amino acid derivatives |
| JP7096957B2 (ja) * | 2020-07-13 | 2022-07-06 | 日本碍子株式会社 | 精製方法 |
| CN113552250A (zh) * | 2021-06-30 | 2021-10-26 | 海南海灵化学制药有限公司 | 一种盐酸头孢唑兰的杂质检测方法 |
| WO2024263708A2 (en) * | 2023-06-23 | 2024-12-26 | Board Of Trustees Of Michigan State University | Ornithine decarboxylase (odc) inhibitors and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5038509B1 (enExample) | 1970-10-21 | 1975-12-10 | ||
| GB1589317A (en) | 1977-11-24 | 1981-05-13 | Lilly Co Eli | Freeze drying cephalothin sodium |
| JPS6019759B2 (ja) | 1977-11-24 | 1985-05-17 | イ−ライ・リリ−・アンド・カンパニ− | 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号 |
| JPS60255723A (ja) | 1984-05-31 | 1985-12-17 | Ono Pharmaceut Co Ltd | メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法 |
| JPH07117533B2 (ja) | 1985-08-28 | 1995-12-18 | 株式会社生体科学研究所 | トランスフエリンおよびその用途 |
| US20030220521A1 (en) | 1989-07-27 | 2003-11-27 | G.D. Searle & Co. | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension |
| TW264475B (enExample) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| JP2843444B2 (ja) | 1994-05-02 | 1999-01-06 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法 |
| CN1048248C (zh) | 1994-05-02 | 2000-01-12 | 盐野义制药株式会社 | 吡咯烷基硫基碳代青霉烯衍生物的结晶、含该结晶的冷冻干燥制剂及其制造方法 |
| DE19531874C1 (de) | 1995-08-30 | 1996-10-02 | Daimler Benz Ag | Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
| SI2231667T1 (sl) * | 2008-01-18 | 2013-12-31 | Merck Sharp & Dohme Corp. | Beta laktamazni inhibitorji |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| JP2012122603A (ja) | 2010-11-15 | 2012-06-28 | Nifco Inc | コネクタ装置 |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| CN104892490B (zh) | 2010-12-22 | 2017-07-21 | 明治制果药业株式会社 | 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物 |
| WO2012172368A1 (en) | 2011-06-17 | 2012-12-20 | Astrazeneca Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
| KR101512738B1 (ko) | 2011-08-27 | 2015-04-17 | 욱크하르트 리미티드 | 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도 |
| JP5677634B2 (ja) | 2011-08-30 | 2015-02-25 | ウォックハート リミテッド | １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用 |
| EP3052497B1 (en) | 2011-09-13 | 2017-06-28 | Wockhardt Limited | Nitrogen containing compounds and their use |
| US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| UA117734C2 (uk) | 2012-05-30 | 2018-09-25 | Мейдзі Сейка Фарма Ко., Лтд. | НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ |
| BR112015003592B1 (pt) * | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
| MY176278A (en) | 2013-09-24 | 2020-07-27 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative and intermediate thereof |
| NZ757221A (en) | 2013-10-08 | 2021-12-24 | Meiji Seika Pharma Co Ltd | Crystalline forms of diazabicyclooctane derivative and production process thereof |
| BR112016022437A2 (pt) | 2014-03-29 | 2017-08-15 | Wockhardt Ltd | Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio |
| BR112017010445B8 (pt) | 2014-12-05 | 2024-02-27 | Meiji Seika Pharma Co Ltd | Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável |
-
2014
- 2014-10-08 NZ NZ757221A patent/NZ757221A/en unknown
- 2014-10-08 AR ARP140103759A patent/AR097971A1/es not_active Application Discontinuation
- 2014-10-08 NZ NZ719568A patent/NZ719568A/en unknown
- 2014-10-08 EP EP14852849.0A patent/EP3067355B1/en active Active
- 2014-10-08 US US15/027,956 patent/US10131665B2/en active Active
- 2014-10-08 CN CN201480055342.1A patent/CN105612159A/zh active Pending
- 2014-10-08 CA CA3110803A patent/CA3110803C/en active Active
- 2014-10-08 MX MX2016004506A patent/MX361659B/es active IP Right Grant
- 2014-10-08 WO PCT/JP2014/076875 patent/WO2015053297A1/ja not_active Ceased
- 2014-10-08 TW TW103134993A patent/TWI673269B/zh active
- 2014-10-08 BR BR122022016622-9A patent/BR122022016622B1/pt active IP Right Grant
- 2014-10-08 CA CA2926071A patent/CA2926071C/en active Active
- 2014-10-08 ES ES14852849T patent/ES2842225T3/es active Active
- 2014-10-08 ES ES17195437T patent/ES2901198T3/es active Active
- 2014-10-08 MY MYPI2019007794A patent/MY199066A/en unknown
- 2014-10-08 HK HK16107473.3A patent/HK1219479A1/zh unknown
- 2014-10-08 DK DK14852849.0T patent/DK3067355T3/da active
- 2014-10-08 KR KR1020227012598A patent/KR102487297B1/ko active Active
- 2014-10-08 AU AU2014332960A patent/AU2014332960B2/en not_active Ceased
- 2014-10-08 MX MX2018015407A patent/MX383661B/es unknown
- 2014-10-08 RU RU2016116501A patent/RU2695219C2/ru active
- 2014-10-08 KR KR1020167009770A patent/KR102388529B1/ko active Active
- 2014-10-08 CN CN202010091853.6A patent/CN111153903A/zh active Pending
- 2014-10-08 NZ NZ757220A patent/NZ757220A/en not_active IP Right Cessation
- 2014-10-08 JP JP2015541603A patent/JP6617029B2/ja active Active
- 2014-10-08 EP EP19202413.1A patent/EP3613741A1/en not_active Withdrawn
- 2014-10-08 EP EP17195437.3A patent/EP3299370B1/en active Active
- 2014-10-08 HU HUE14852849A patent/HUE051925T2/hu unknown
- 2014-10-08 EP EP19202412.3A patent/EP3613740A1/en not_active Withdrawn
- 2014-10-08 NZ NZ757222A patent/NZ757222A/en unknown
- 2014-10-08 SG SG11201602723RA patent/SG11201602723RA/en unknown
- 2014-10-08 BR BR112016006266-3A patent/BR112016006266B1/pt active IP Right Grant
- 2014-10-08 NZ NZ743374A patent/NZ743374A/en unknown
-
2016
- 2016-03-29 ZA ZA2016/02054A patent/ZA201602054B/en unknown
- 2016-04-06 IL IL244969A patent/IL244969B/en unknown
-
2018
- 2018-10-01 US US16/148,774 patent/US10604522B2/en active Active
-
2019
- 2019-09-20 JP JP2019171587A patent/JP6995810B2/ja active Active
-
2020
- 2020-02-18 US US16/793,843 patent/US11414417B2/en active Active
-
2021
- 2021-09-07 JP JP2021145422A patent/JP7182677B2/ja active Active
- 2021-12-22 IL IL289275A patent/IL289275B2/en unknown
-
2022
- 2022-07-07 US US17/859,015 patent/US12221443B2/en active Active
-
2024
- 2024-03-01 AR ARP240100517A patent/AR132030A2/es unknown
- 2024-03-01 AR ARP240100516A patent/AR132029A2/es unknown
- 2024-03-01 AR ARP240100515A patent/AR132028A2/es unknown
- 2024-10-22 US US18/922,948 patent/US20250059191A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097971A1 (es) | Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas | |
| BR112014026908A2 (pt) | síntese direta de cu-sapo-34 com base na combinação de um complexo de cobre-poliamina e uma molécula orgânica adicional, e suas implicações catalíticas | |
| BR112013011593A2 (pt) | cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo | |
| NZ718607A (en) | Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines | |
| BR112012016473A2 (pt) | ligando bidentado, processo para a carbonilação de compostos etilenicamente insaturados, complexo, e, sistema catalisador | |
| BR112015019257A2 (pt) | métodos para produzir de modo controlável um catalisador fischer-tropsch contendo hematita e para produzir produto hidrocarboneto fischer-tropsch, produto, e, catalisador fischer-tropsch contendo hematita | |
| MX2016001096A (es) | Sales de dasatinib en forma amorfa. | |
| RU2017123112A (ru) | Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированого препарата | |
| CO6700138A1 (es) | Procedimiento de preparación de sal de l-arginina de perindoprilo | |
| BR112015021853A2 (pt) | processo de carbonilação | |
| MY165005A (en) | Process for preparing and purifying salts of acrylamido-2-methylpropanesulfonic acid | |
| BR112016010262A8 (pt) | processo para preparar um catalisador de hidrotratamento | |
| MX2016001095A (es) | Sales de dasatinib en forma cristalina. | |
| AR075340A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a,formas cristalinas 1, 2 y 3, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento util para el tratamiento de enfermedades inflamatorias | |
| RU2013144861A (ru) | Способ синтеза нанокомпозита feco/c на основе полиакрилонитрила | |
| BR112015025267A2 (pt) | processo melhorado para hidróxido de colina | |
| TN2016000269A1 (en) | Water soluble crystallin salts of certain harringtonines unambiguously protonated on their alkaloid nitrogen and their use as chemotherapeutic drugs. | |
| BR112015000988A2 (pt) | método para a síntese de ácido n-fosfonometiliminodiacético ou derivados do mesmo | |
| AR086310A1 (es) | Solvente mejorado para la recuperacion de anhidrido maleico a partir de una corriente de gas | |
| AR107793A1 (es) | Sistemas catalizadores selectivos y procedimiento para la producción de espinetoram | |
| SA112330994B1 (ar) | عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً | |
| WO2015084693A3 (en) | New process for preparing loratadine from a ketone intermediate | |
| BR112022013216A2 (pt) | Produção contínua de hidratos de clatrato a partir de correntes aquosas e formadoras de hidratos, métodos e usos dos mesmos. | |
| BR112014029361A2 (pt) | método de produção de ácido tereftálico e seus derivados | |
| RU2013151044A (ru) | Способ получения кобальтита лития |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |